Literature DB >> 27279372

Autoantibody-Mediated Pulmonary Alveolar Proteinosis in Rasgrp1-Deficient Mice.

Andrew Ferretti1, Jarrod R Fortwendel1, Sarah A Gebb2, Robert A Barrington3.   

Abstract

Pulmonary alveolar proteinosis (PAP) is a rare lung syndrome caused by the accumulation of surfactants in the alveoli. The most prevalent clinical form of PAP is autoimmune PAP (aPAP) whereby IgG autoantibodies neutralize GM-CSF. GM-CSF is a pleiotropic cytokine that promotes the differentiation, survival, and activation of alveolar macrophages, the cells responsible for surfactant degradation. IgG-mediated neutralization of GM-CSF thereby inhibits alveolar macrophage homeostasis and function, leading to surfactant accumulation and innate immunodeficiency. Importantly, there are no rodent models for this disease; therefore, underlying immune mechanisms regulating GM-CSF-specific IgG in aPAP are not well understood. In this article, we identify that autoimmune-prone Rasgrp1-deficient mice develop aPAP: 1) Rasgrp1-deficient mice exhibit reduced pulmonary compliance and lung histopathology characteristic of PAP; 2) alveolar macrophages from Rasgrp1-deficient mice are enlarged and exhibit reduced surfactant degradation; 3) the concentration of GM-CSF-specific IgG is elevated in both serum and bronchoalveolar lavage fluid from Rasgrp1-deficient mice; 4) GM-CSF-specific IgG is capable of neutralizing GM-CSF bioactivity; and 5) Rasgrp1-deficient mice also lacking CD275/ICOSL, a molecule necessary for conventional T cell-dependent Ab production, have reduced GM-CSF-specific autoantibody and do not develop PAP. Collectively, these studies reveal that Rasgrp1-deficient mice, to our knowledge, represent the first rodent model for aPAP.
Copyright © 2016 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27279372      PMCID: PMC4935575          DOI: 10.4049/jimmunol.1502248

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  55 in total

1.  Neutralization of endogenous granulocyte-macrophage colony-stimulating factor subverts the protective immune response to Histoplasma capsulatum.

Authors:  G S Deepe; R Gibbons; E Woodward
Journal:  J Immunol       Date:  1999-11-01       Impact factor: 5.422

2.  ICOS receptor instructs T follicular helper cell versus effector cell differentiation via induction of the transcriptional repressor Bcl6.

Authors:  Youn Soo Choi; Robin Kageyama; Danelle Eto; Tania C Escobar; Robert J Johnston; Laurel Monticelli; Christopher Lao; Shane Crotty
Journal:  Immunity       Date:  2011-06-24       Impact factor: 31.745

3.  Multiple checkpoint breach of B cell tolerance in Rasgrp1-deficient mice.

Authors:  Amber Bartlett; Janet E Buhlmann; James Stone; Bing Lim; Robert A Barrington
Journal:  J Immunol       Date:  2013-08-30       Impact factor: 5.422

4.  IgM-type GM-CSF autoantibody is etiologically a bystander but associated with IgG-type autoantibody production in autoimmune pulmonary alveolar proteinosis.

Authors:  Takahito Nei; Shinya Urano; Natsuki Motoi; Jun Takizawa; Chinatsu Kaneko; Hiroko Kanazawa; Ryushi Tazawa; Kazuhide Nakagaki; Kiyoko S Akagawa; Keiichi Akasaka; Toshio Ichiwata; Arata Azuma; Koh Nakata
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-02-24       Impact factor: 5.464

5.  Therapeutic effectiveness of rituximab in a patient with unresponsive autoimmune pulmonary alveolar proteinosis.

Authors:  Anat Amital; Shlomo Dux; David Shitrit; Ofer Shpilberg; Mordechai R Kramer
Journal:  Thorax       Date:  2010-09-20       Impact factor: 9.139

6.  Human ICOS deficiency abrogates the germinal center reaction and provides a monogenic model for common variable immunodeficiency.

Authors:  Klaus Warnatz; Lukas Bossaller; Ulrich Salzer; Andrea Skrabl-Baumgartner; Wolfgang Schwinger; Mirjam van der Burg; Jacques J M van Dongen; Marzena Orlowska-Volk; Rolf Knoth; Anne Durandy; Ruth Draeger; Michael Schlesier; Hans Hartmut Peter; Bodo Grimbacher
Journal:  Blood       Date:  2005-12-29       Impact factor: 22.113

7.  An open-label trial of rituximab therapy in pulmonary alveolar proteinosis.

Authors:  M S Kavuru; A Malur; I Marshall; B P Barna; M Meziane; I Huizar; H Dalrymple; R Karnekar; M J Thomassen
Journal:  Eur Respir J       Date:  2011-04-08       Impact factor: 16.671

8.  PU.1 regulation of human alveolar macrophage differentiation requires granulocyte-macrophage colony-stimulating factor.

Authors:  Tracey L Bonfield; Baisakhi Raychaudhuri; Anagha Malur; Susamma Abraham; Bruce C Trapnell; Mani S Kavuru; Mary Jane Thomassen
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2003-08-01       Impact factor: 5.464

9.  Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor.

Authors:  T Kitamura; N Tanaka; J Watanabe; S Kanegasaki; Y Yamada; K Nakata
Journal:  J Exp Med       Date:  1999-09-20       Impact factor: 14.307

10.  Familial pulmonary alveolar proteinosis caused by mutations in CSF2RA.

Authors:  Takuji Suzuki; Takuro Sakagami; Bruce K Rubin; Lawrence M Nogee; Robert E Wood; Sarah L Zimmerman; Teresa Smolarek; Megan K Dishop; Susan E Wert; Jeffrey A Whitsett; Gregory Grabowski; Brenna C Carey; Carrie Stevens; Johannes C M van der Loo; Bruce C Trapnell
Journal:  J Exp Med       Date:  2008-10-27       Impact factor: 14.307

View more
  5 in total

1.  Investigating global gene expression changes in a murine model of cherubism.

Authors:  Tulika Sharma; Justin Cotney; Vijender Singh; Archana Sanjay; Ernst J Reichenberger; Yasuyoshi Ueki; Peter Maye
Journal:  Bone       Date:  2020-03-10       Impact factor: 4.398

2.  CISH attenuates homeostatic cytokine signaling to promote lung-specific macrophage programming and function.

Authors:  Karsen E Shoger; Neha Cheemalavagu; Yuqi M Cao; Brandon A Michalides; Virendra K Chaudhri; Jonathan A Cohen; Harinder Singh; Rachel A Gottschalk
Journal:  Sci Signal       Date:  2021-08-31       Impact factor: 8.192

3.  Correction of a chronic pulmonary disease through lentiviral vector-mediated protein expression.

Authors:  Helena Lund-Palau; Claudia Ivette Juarez-Molina; Cuixiang Meng; Anushka Bhargava; Aikaterini Pilou; Kiran Aziz; Nora Clarke; Naoko Atsumi; Ali Ashek; Michael R Wilson; Masao Takata; Simon Padley; Deborah R Gill; Stephen C Hyde; Cliff Morgan; Eric W F W Alton; Uta Griesenbach
Journal:  Mol Ther Methods Clin Dev       Date:  2022-04-14       Impact factor: 5.849

4.  Novel Mutations in RASGRP1 are Associated with Immunodeficiency, Immune Dysregulation, and EBV-Induced Lymphoma.

Authors:  Ido Somekh; Benjamin Marquardt; Yanshan Liu; Meino Rohlfs; Sebastian Hollizeck; Musa Karakukcu; Ekrem Unal; Ebru Yilmaz; Turkan Patiroglu; Murat Cansever; Shirly Frizinsky; Vicktoria Vishnvenska-Dai; Erez Rechavi; Tali Stauber; Amos J Simon; Atar Lev; Christoph Klein; Daniel Kotlarz; Raz Somech
Journal:  J Clin Immunol       Date:  2018-07-20       Impact factor: 8.317

5.  Prevalence and correlation of cytokine-specific autoantibodies with epidemiological factors and C-reactive protein in 8,972 healthy individuals: Results from the Danish Blood Donor Study.

Authors:  Jakob Hjorth von Stemann; Andreas Stribolt Rigas; Lise Wegner Thørner; Daniel Guldager Kring Rasmussen; Ole Birger Pedersen; Klaus Rostgaard; Christian Erikstrup; Henrik Ullum; Morten Bagge Hansen
Journal:  PLoS One       Date:  2017-06-30       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.